Addressing the Psychosocial Impacts of Inflammatory Skin Conditions in Patient Care
Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to atopic dermatitis, psoriasis, and hidradenitis suppurativa.
FDA Delays UCB’s Bimekizumab Approval
FDA action is no longer expected in Q3 of 2023.